{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T15:46:11Z","timestamp":1760888771463},"reference-count":66,"publisher":"Elsevier BV","issue":"5","content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Gastroenterology"],"published-print":{"date-parts":[[2012,10]]},"DOI":"10.1016\/j.bpg.2012.11.006","type":"journal-article","created":{"date-parts":[[2013,2,5]],"date-time":"2013-02-05T00:34:44Z","timestamp":1360024484000},"page":"601-610","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Current and emerging strategies in the management of\u00a0Crohn's disease"],"prefix":"10.1016","volume":"26","author":[{"given":"Charles","family":"Randall","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Vizuete","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregg","family":"Wendorf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Balaji","family":"Ayyar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory","family":"Constantine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.bpg.2012.11.006_bib1","first-page":"263","article-title":"Regional ileitis: a pathological and clinical entity","volume":"67","author":"Crohn","year":"1932","journal-title":"Mt Sinai J Med"},{"key":"10.1016\/j.bpg.2012.11.006_bib2","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S0016-5085(76)80163-1","article-title":"Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study","volume":"70","author":"Best","year":"1974","journal-title":"Gastroenterology"},{"issue":"8167","key":"10.1016\/j.bpg.2012.11.006_bib3","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S0140-6736(80)92767-1","article-title":"A simple index of Crohn's-disease activity","volume":"1","author":"Harvey","year":"1980","journal-title":"Lancet"},{"key":"10.1016\/j.bpg.2012.11.006_bib4","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.cgh.2010.01.001","article-title":"Correlation between the Crohn's disease activity and Harvey-Bradshaw indices in assessing Crohn's disease severity","volume":"4","author":"Vermeire","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.bpg.2012.11.006_bib5","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/0016-5085(89)90905-0","article-title":"A new measure of health status for clinical trials in inflammatory bowel disease","volume":"96","author":"Guyatt","year":"1989","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bpg.2012.11.006_bib6","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0016-5107(04)01878-4","article-title":"Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD","volume":"60","author":"Daperno","year":"2004","journal-title":"Gastrointest Endosc"},{"key":"10.1016\/j.bpg.2012.11.006_bib7","doi-asserted-by":"crossref","unstructured":"Singleton JW, Hanauer SB, Gitnick GL, Peppercorn MA, Robinson MG, Wruble LD et\u00a0al. Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Pentasa Crohn's Disease Study Group. Gastroenterology;104:1293\u20131301.","DOI":"10.1016\/0016-5085(93)90337-C"},{"key":"10.1016\/j.bpg.2012.11.006_bib8","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S1542-3565(04)00122-3","article-title":"Oral pentasa in the treatment of active Crohn\u2019s disease: a meta-analysis of double-blind, placebo-controlled trials","volume":"2","author":"Hanauer","year":"2004","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.bpg.2012.11.006_bib9","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1177\/1756283X11405250","article-title":"Optimizing clinical use of mesalamine (5-aminosalicylic acid) in inflammatory bowel disease","volume":"4","author":"Williams","year":"2011","journal-title":"Ther Adv Gastroenterol"},{"key":"10.1016\/j.bpg.2012.11.006_bib10","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD008870","article-title":"Aminosalicylates for induction of remission or response in Crohn\u2019s disease","volume":"12","author":"Lim","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"10.1016\/j.bpg.2012.11.006_bib11","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1053\/gast.2001.26279","article-title":"The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study","volume":"121","author":"Faubion","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bpg.2012.11.006_bib12","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/0016-5085(79)90385-8","article-title":"National Cooperative Crohn\u2019s Disease Study: results of drug treatment","volume":"77","author":"Summers","year":"1979","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bpg.2012.11.006_bib13","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/0016-5085(84)90409-8","article-title":"European Cooperative Crohn\u2019s Disease Study: results of drug treatment","volume":"86","author":"Malchow","year":"1984","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.bpg.2012.11.006_bib14","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/S0016-5085(98)70254-9","article-title":"Budesonide versus prednisone in the treatment of active Crohn's disease","volume":"115","author":"Barmeir","year":"1998","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bpg.2012.11.006_bib15","doi-asserted-by":"crossref","first-page":"V1","DOI":"10.1136\/gut.2004.043372","article-title":"Guidelines for the management of inflammatory bowel disease in adults","volume":"53","author":"Carter","year":"2004","journal-title":"Gut"},{"key":"10.1016\/j.bpg.2012.11.006_bib16","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1053\/gast.1996.v110.pm8536887","article-title":"Oral budesonide as maintenance treatment for Crohn\u2019s disease: a placebo-controlled, dose-ranging study","volume":"110","author":"Greenberg","year":"1996","journal-title":"Gastroenterology"},{"issue":"8","key":"10.1016\/j.bpg.2012.11.006_bib17","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1046\/j.1365-2036.2002.01289.x","article-title":"Systematic review: the effectiveness of budesonide therapy for Crohn's disease","volume":"16","author":"Kane","year":"2002","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.bpg.2012.11.006_bib18","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1111\/j.1572-0241.2005.41992.x","article-title":"Budesonide for maintenance of remission in patients with Crohn's disease in medically induced remission: a predetermined pooled analysis of four randomized, double-blind, placebo-controlled trials","volume":"100","author":"Sandborn","year":"2005","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"10.1016\/j.bpg.2012.11.006_bib19","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1136\/gut.41.2.209","article-title":"Oral budesonide is as effective as oral prednisolone in active Crohn's disease","volume":"41","author":"Campieri","year":"1997","journal-title":"Gut"},{"issue":"13","key":"10.1016\/j.bpg.2012.11.006_bib20","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1056\/NEJM199409293311304","article-title":"A comparison of budesonide with prednisolone for active Crohn's disease","volume":"331","author":"Rutgeerts","year":"1994","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.bpg.2012.11.006_bib21","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1046\/j.1365-2036.1998.00321.x","article-title":"Bone turnover during short-term therapy with methylprednisolone or budesonide in Crohn's disease","volume":"12","author":"D'haens","year":"1998","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.bpg.2012.11.006_bib22","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJM199409293311303","article-title":"Oral budesonide for active Crohn's disease","volume":"331","author":"Greenberg","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bpg.2012.11.006_bib23","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/j.1365-2036.2005.02338.x","article-title":"Budesonide as maintenance treatment in Crohn's disease: a placebo-controlled trial","volume":"21","author":"Hanauer","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.bpg.2012.11.006_bib24","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1046\/j.1365-2036.1998.00285.x","article-title":"Oral budesonide as maintenance therapy in Crohn's disease-results of a 12-month study","volume":"12","author":"Ferguson","year":"1998","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.bpg.2012.11.006_bib25","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1136\/gut.39.1.82","article-title":"Budesonide prolongs time to relapse in ileal and ileocaecal Crohn's disease. A placebo controlled one year study","volume":"39","author":"Lofberg","year":"1996","journal-title":"Gut"},{"issue":"3","key":"10.1016\/j.bpg.2012.11.006_bib26","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1136\/gut.35.3.360","article-title":"Frequency of glucocorticoid resistance and dependency in Crohn's disease","volume":"35","author":"Munkholm","year":"1994","journal-title":"Gut"},{"issue":"18","key":"10.1016\/j.bpg.2012.11.006_bib27","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJM198005013021801","article-title":"Treatment of Crohn's disease with 6-mercaptopurine","volume":"302","author":"Present","year":"1980","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.bpg.2012.11.006_bib28","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1136\/gut.37.5.674","article-title":"A controlled double blind study of azathioprine in the management of Crohn's disease","volume":"37","author":"Candy","year":"1995","journal-title":"Gut"},{"key":"10.1016\/j.bpg.2012.11.006_bib29","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/0016-5085(93)90709-L","article-title":"Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn's disease","volume":"105","author":"Ewe","year":"1993","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bpg.2012.11.006_bib30","doi-asserted-by":"crossref","first-page":"3248","DOI":"10.1111\/j.1572-0241.1999.01530.x","article-title":"Malignant neoplasms subsequent to treatment of inflammatory bowel disease with 6-mercaptopurine","volume":"94","author":"Korelitz","year":"1999","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"10.1016\/j.bpg.2012.11.006_bib31","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1056\/NEJM199502023320503","article-title":"Methotrexate for the treatment of Crohn's disease","volume":"332","author":"Feagan","year":"1995","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.bpg.2012.11.006_bib32","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJM200006013422202","article-title":"A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease","volume":"342","author":"Feagan","year":"2000","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.bpg.2012.11.006_bib33","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/j.1365-2036.2007.03455.x","article-title":"Medical management of mild to moderate Crohn\u2019s disease: evidence-based treatment algorithms for induction and maintenance of remission","volume":"26","author":"Sandborn","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.bpg.2012.11.006_bib34","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Maintenance infliximab for Crohn\u2019s disease: the ACCENT I randomized trial","volume":"359","author":"Hanauer","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.bpg.2012.11.006_bib35","first-page":"1026","article-title":"Endoscopic and histological healing with infliximab anti-tumer necrosis factor antibodies in Crohn\u2019s disease: a European multicenter trial","volume":"116","author":"D\u2019Haens","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bpg.2012.11.006_bib36","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1056\/NEJMoa030815","article-title":"Infliximab maintenance therapy for fistulizing Crohn's disease","volume":"350","author":"Sands","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bpg.2012.11.006_bib37","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","article-title":"Infliximab, azathioprine, or combination therapy for Crohn's disease","volume":"362","author":"Colombel","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bpg.2012.11.006_bib38","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD006893","article-title":"Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease","volume":"1","author":"Behm","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.bpg.2012.11.006_bib39","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1053\/j.gastro.2005.11.030","article-title":"Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial","volume":"130","author":"Hanauer","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bpg.2012.11.006_bib40","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1136\/gut.2006.106781","article-title":"Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II Trial","volume":"56","author":"Sandborn","year":"2007","journal-title":"Gut"},{"key":"10.1016\/j.bpg.2012.11.006_bib41","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1053\/j.gastro.2006.11.041","article-title":"Adalimumab for maintenance of clinical response and remission in patients with Crohn\u2019s disease: the CHARM Trial","volume":"132","author":"Colombel","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bpg.2012.11.006_bib42","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1053\/j.gastro.2012.01.035","article-title":"Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial","volume":"142","author":"Rutgeerts","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bpg.2012.11.006_bib43","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1002\/ibd.21870","article-title":"Recommendations for the treatment of Crohn's disease with tumor necrosis factor antagonists: an expert consensus report","volume":"18","author":"Feagan","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.bpg.2012.11.006_bib44","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.cgh.2008.03.014","article-title":"Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials","volume":"6","author":"Peyrin-Biroulet","year":"2008","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.bpg.2012.11.006_bib45","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1053\/j.gastro.2005.06.064","article-title":"A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease","volume":"129","author":"Schreiber","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bpg.2012.11.006_bib46","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1056\/NEJMoa062897","article-title":"Maintenance therapy with certolizumab pegol for Crohn's disease","volume":"357","author":"Schreiber","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bpg.2012.11.006_bib47","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.cgh.2010.04.021","article-title":"Certolizumab pegol in patients with moderate to severe Crohn's disease and secondary failure to infliximab","volume":"8","author":"Sandborn","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.bpg.2012.11.006_bib48","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa067594","article-title":"Certolizumab pegol for the treatment of Crohn's disease","volume":"357","author":"Sandborn","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bpg.2012.11.006_bib49","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa020732","article-title":"Natalizumab for active Crohn\u2019s disease","volume":"348","author":"Ghosh","year":"2003","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.bpg.2012.11.006_bib50","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1053\/j.gastro.2007.03.024","article-title":"Natalizumab for the treatment of active Crohn's disease: results of the ENCORE trial","volume":"132","author":"Targan","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bpg.2012.11.006_bib51","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD006097.pub2","article-title":"Natalizumab for induction of remission in Crohn's disease","volume":"1","author":"MacDonald","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.bpg.2012.11.006_bib52","first-page":"328","article-title":"An antibiotic regimen for the treatment of active Crohn\u2019s disease: a randomized, controlled clinical trial of metronidazole plus ciprofloxacin","volume":"91","author":"Prantera","year":"1996","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.bpg.2012.11.006_bib53","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1007\/s10620-009-1111-y","article-title":"Adjunctive antibiotic therapy with Rifaximin may help reduce Crohn\u2019s disease activity","volume":"55","author":"Shafran","year":"2010","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.bpg.2012.11.006_bib54","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1053\/j.gastro.2011.11.032","article-title":"Rifaximin-extended intestinal release induces remission in patients with moderately active Crohn\u2019s disease","volume":"142","author":"Prantera","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bpg.2012.11.006_bib55","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1007\/s11894-012-0265-5","article-title":"Probiotics for the treatment of inflammatory bowel disease","volume":"14","author":"Veerappan","year":"2012","journal-title":"Curr Gastroenterol Rep"},{"key":"10.1016\/j.bpg.2012.11.006_bib56","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/ajg.2011.44","article-title":"Dietary intake and risk of developing inflammatory bowel disease: a systematic review of the literature","volume":"106","author":"Hou","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.bpg.2012.11.006_bib57","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/0140-6736(93)92121-9","article-title":"Treatment of active Crohn\u2019s disease by exclusion diet: East Anglian multicentre controlled trial","volume":"342","author":"Riordan","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/j.bpg.2012.11.006_bib58","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1177\/0148607195019005356","article-title":"How effective is enteral nutrition in inducing clinical remission in active Crohn\u2019s disease? A meta-analysis of the randomized clinical trials","volume":"19","author":"Fern\u00e1ndez-Banares","year":"1995","journal-title":"J Parenter Enteral Nutr"},{"key":"10.1016\/j.bpg.2012.11.006_bib59","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/0016-5085(95)90203-1","article-title":"Meta-analysis of enteral nutrition as a primary treatment of active Crohn\u2019s disease","volume":"108","author":"Griffiths","year":"1995","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bpg.2012.11.006_bib60","doi-asserted-by":"crossref","first-page":"267","DOI":"10.3109\/00365529609004877","article-title":"Defined-formula diets versus steroids in the treatment of active Crohn\u2019s disease: a meta-analysis","volume":"31","author":"Messori","year":"1996","journal-title":"Scand J Gastroenterol"},{"issue":"1","key":"10.1016\/j.bpg.2012.11.006_bib61","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD000542.pub2","article-title":"Enteral nutritional therapy for induction of remission in Crohn's disease","author":"Zachos","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.bpg.2012.11.006_bib62","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.dld.2012.03.007","article-title":"Nutritional therapy versus 6-mercaptopurine as maintenance therapy in patients with Crohn\u2019s disease","volume":"44","author":"Hanai","year":"2012","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.bpg.2012.11.006_bib63","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0002-9440(10)65128-0","article-title":"Increased expression of IP-10, IL-8, MCP1, and MCP3 in ulcerative colitis","volume":"155","author":"Uguccioni","year":"1999","journal-title":"Am J Pathol"},{"issue":"3","key":"10.1016\/j.bpg.2012.11.006_bib64","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1124\/jpet.109.153973","article-title":"The binding specificity and selective antagonism of vedolizumab, an anti-alpha 4, beta 7 integrin therapeutic antibody in development for inflammatory bowel disease","volume":"330","author":"Soler","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.bpg.2012.11.006_bib65","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/j.1440-1827.2007.02117.x","article-title":"Blockade of interferon-gamma-inducible protein-10 attenuates chronic experimental colitis by blocking cellular trafficking and protecting intestinal epithelial cells","volume":"57","author":"Suzuki","year":"2007","journal-title":"Pathol Int"},{"issue":"Suppl.","key":"10.1016\/j.bpg.2012.11.006_bib66","article-title":"W117 CXCL 10 expression and biological activity in inflammatory bowel disease","volume":"134","author":"Witte","year":"2008","journal-title":"Gastroenterology"}],"container-title":["Best Practice & Research Clinical Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521691812001059?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521691812001059?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,9]],"date-time":"2019-07-09T07:09:38Z","timestamp":1562656178000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521691812001059"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10]]},"references-count":66,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["S1521691812001059"],"URL":"https:\/\/doi.org\/10.1016\/j.bpg.2012.11.006","relation":{},"ISSN":["1521-6918"],"issn-type":[{"value":"1521-6918","type":"print"}],"subject":[],"published":{"date-parts":[[2012,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current and emerging strategies in the management of\u00a0Crohn's disease","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bpg.2012.11.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}